Normal Pressure Hydrocephalus (NPH): Diagnostic Workup and Treatment
For elderly patients with suspected idiopathic normal pressure hydrocephalus (iNPH), obtain brain MRI or CT without contrast to confirm ventriculomegaly, perform a high-volume CSF tap test (30-50 mL removal) with pre- and post-drainage gait assessment, and if positive, proceed directly to ventriculoperitoneal shunt placement, which offers 80-90% chance of symptom improvement including reversal of dementia. 1, 2
Clinical Presentation: The Classic Triad
Look specifically for these three features appearing in sequence:
- Gait disturbance (appears first): Magnetic, shuffling, wide-based gait with difficulty initiating steps
- Urinary dysfunction: Urge incontinence, frequency, nocturia (not simply attributed to diuretics or prostate issues)
- Cognitive impairment: Frontal-subcortical pattern with psychomotor slowing, impaired executive function, and apathy (not primarily memory loss like Alzheimer's)
Critical caveat: Patients may present with atypical features including focal deficits, aphasia, or hemiplegia that mimic stroke, creating diagnostic confusion 3. Maintain high suspicion even with atypical presentations in elderly patients with ventriculomegaly.
Diagnostic Algorithm
Step 1: Brain Imaging (First-Line)
Order MRI head without contrast OR CT head without contrast - these are equivalent initial options 1. Look for:
- Ventriculomegaly: Evans index >0.3 (maximal width of frontal horns/maximal width of inner skull)
- Disproportionately enlarged temporal horns and third ventricle
- Callosal angle <90 degrees
- Transependymal CSF flow (periventricular T2/FLAIR hyperintensity)
- Minimal cortical atrophy (ventricles enlarged out of proportion to sulci)
- Hyperdynamic aqueductal CSF flow void on MRI (suggests shunt responsiveness) 1
Do NOT order: Contrast-enhanced studies are unnecessary for iNPH diagnosis. MR spectroscopy does not help differentiate iNPH from other dementias 1.
Step 2: CSF Tap Test (Diagnostic and Prognostic)
Perform high-volume lumbar puncture removing 30-50 mL CSF 4, 2, 5:
- Measure opening pressure (typically normal: 70-245 mm H2O)
- Conduct standardized gait testing immediately before and 2-4 hours after CSF removal
- Document timed walking tests, number of steps, turning ability
- Assess cognitive function with simple bedside tests
Positive tap test = objective improvement in gait (faster walking speed, fewer steps, improved turning) and predicts 80-90% shunt response rate 2.
Step 3: Extended Lumbar Drainage (If Tap Test Equivocal)
If single tap test is negative but clinical suspicion remains high:
- Place temporary spinal catheter for external lumbar drainage over 3-5 days
- Remove 10-15 mL CSF per hour
- Repeat gait assessments daily
- This increases diagnostic sensitivity for shunt-responsive patients 2, 5
Step 4: Rule Out Comorbid Pathology
Critical consideration: 32% of iNPH patients have coexisting Alzheimer's pathology and 31% have α-synucleinopathies 6. These significantly impact shunt outcomes.
Consider CSF biomarker testing in patients with:
- Prominent memory loss (suggests Alzheimer's co-pathology)
- Parkinsonism beyond gait disorder (suggests Lewy body disease)
- Atypical features or poor tap test response
Send CSF for: Aβ42, total tau, phospho-tau (Alzheimer's markers) 6
Consider α-synuclein skin biopsy if parkinsonian features present 6
Treatment: Surgical Shunting
Definitive Management
Ventriculoperitoneal shunt placement is the only effective treatment for properly selected patients 7, 2, 5.
Shunt selection:
- Programmable valve systems are preferred - allow non-invasive pressure adjustments postoperatively
- Antibiotic-impregnated catheters reduce infection risk (though this evidence is primarily from pediatric literature) 8
Expected outcomes in properly selected patients:
- 80-90% show improvement in symptoms 2
- All three symptoms can improve, including dementia reversal 2, 5
- Gait typically improves first and most dramatically
- Cognitive improvement may take weeks to months 3
Alternative Surgical Approach
Endoscopic third ventriculostomy (ETV) is an alternative to shunting, though evidence comparing outcomes in adults with iNPH is limited. In pediatric hydrocephalus, ETV and shunts show equivalent outcomes 9, but this cannot be directly extrapolated to elderly iNPH patients.
Post-Shunt Management
Follow-Up Assessment
Monitor at regular intervals (typically 6 weeks, 3 months, 6 months, then annually):
- Repeat standardized gait testing
- Cognitive reassessment
- Urinary symptom evaluation
- Imaging to assess ventricular size
Managing Treatment Failure or Symptom Recurrence
If symptoms fail to improve or worsen after initial improvement:
- Evaluate for shunt malfunction: Obtain shunt series radiographs, consider nuclear medicine shunt patency study
- Assess for shunt infection: Fever, headache, altered mental status warrant CSF sampling
- Consider valve pressure adjustment (if programmable shunt)
- Re-evaluate for coexisting neurodegenerative disease: Progressive cognitive decline despite functioning shunt suggests Alzheimer's or other dementia 6
- Treat comorbid conditions: Vascular disease, metabolic disorders, medication effects 5
Common Pitfalls to Avoid
- Don't dismiss iNPH because of "normal" CSF pressure - the name is misleading; pressure is typically normal at time of measurement 1
- Don't attribute all symptoms to "normal aging" - iNPH is treatable and reversible 2
- Don't delay treatment waiting for "pure" iNPH - even patients with some comorbid pathology can benefit from shunting if tap test positive 6
- Don't confuse ventricular enlargement from atrophy (ex vacuo) with true hydrocephalus - look for disproportionate ventricular size relative to sulci 1
- Don't assume urinary symptoms are from prostate/bladder disease alone - they may be part of iNPH triad 4
Key Strength of Evidence
The diagnostic approach is supported by ACR Appropriateness Criteria (2020) 1 providing Level II evidence for imaging recommendations. Treatment recommendations are based on multiple expert consensus guidelines 10, 7, 2 and systematic reviews demonstrating consistent 80-90% response rates in properly selected patients. The tap test has emerged as the most reliable predictor of shunt responsiveness across multiple studies 4, 2, 5.